NASDAQ · BOLT
Bolt Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BOLT: Nov 11, 2026
Bolt Biotherapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.4. The reported EPS for the same quarter last year was $-3.72.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Dec 2026 | $-2.01 | $-2.01 | $-2.01 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks- RTTNews · Oct 23, 3:00 PM EDTBiotech Stocks On Investor Radar – BOLT +66%, LYCA +33%, LUCD, GMAB(RTTNews) – Shares of several biotech companies moved higher following corporate, financing and clinical developments. Bolt Biotherapeutics gained after announcing a reverse merger with Prana Therapies and a $120 million private placement, Lycia Therapeutics surged in its Nasdaq
- RTTNews · Oct 23, 12:44 PM EDTBolt Biotherapeutics Acquires Prana, Secures $120M To Advance PRA-216 Pipeline; Stock Up(RTTNews) – Bolt Biotherapeutics, Inc. (BOLT) announced its acquisition of Prana Therapies, Inc. through a stock-for-stock reverse merger to advance Prana's pipeline of half-life-extended multispecific antibodies developed using its proprietary INSPIRE platform.
- Fintel · Oct 23, 11:09 AM EDTBolt Biotherapeutics, Inc. Acquires Prana Therapies, Inc. and Secures $120 million Private PlacementOn October 23, 2026, Bolt Biotherapeutics, Inc. acquired Prana Therapies, Inc. in a stock-for-stock transaction structured as a reverse merger. Under the terms of the merger agreement, Bolt Biotherapeutics, Inc. issued 430,746 shares of common stock and 16,360.929 shares of Serie
- RTTNews · Oct 23, 9:58 AM EDTBolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement(RTTNews) – Friday, Bolt Biotherapeutics, Inc. (BOLT) announced its acquisition of Prana Therapies, Inc. through a stock-for-stock transaction aimed at advancing Prana's pipeline of half-life-extended multispecific antibodies developed using its proprietary INSPIRE platform.
- RTTNews · Aug 24, 2:22 PM EDTBolt Biotherapeutics Q2 Loss Narrows As Expenses Decline; BDC-4182 Data Expected In Q3(RTTNews) – Bolt Biotherapeutics, Inc. (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, recently reported second-quarter 2026 results, with a narrower operating loss as research and development and administrative expenses declined.
- Zacks · Aug 11, 5:45 PM EDTBolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue EstimatesBolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 10:35 PM EDTOculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue EstimatesOculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 28, 8:15 AM EDTRepligen (RGEN) Beats Q2 Earnings and Revenue EstimatesRepligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · May 29, 6:29 PM EDTRodman & Renshaw Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy RecommendationFintel reports that on May 29, 2026, Rodman & Renshaw initiated coverage of Bolt Biotherapeutics (NasdaqCM:BOLT) with a Buy recommendation. Analyst Price Forecast Suggests 447.78% Upside
- Zacks · May 12, 5:40 PM EDTBolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue EstimatesBolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 12, 5:45 PM EDTBolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue EstimatesBolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Nov 13, 3:33 AM ESTBolt Reports Q3 2025 Financial Results And Highlights Progress Across Oncology Pipeline(RTTNews) – Bolt Biotherapeutics, Inc. (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, today announced its financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update focused on its
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Bolt Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.